Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Abstract:

:The risk of coronary events with non-steroidal anti-inflammatory drugs has been the subject of much debate since the original trial of rofecoxib raised the issue. Since then, over almost 20 years, such risks have been shown in clinical trials of long-term high-dose users, and in observational studies comparing users with non-users. The roles of cyclooxygenase (COX)-2/COX-1 selectivity and COX-2 inhibitory potency have been proposed to explain this increased risk of myocardial infarction (MI). Among NSAIDs, diclofenac appeared to be associated with a relatively higher risk of MI, similar to that of rofecoxib, compatible with the drug's high COX-2 inhibitory potency. Recent studies have resulted in further information being available. A study in the Danish healthcare system using active comparators found a slightly increased risk of MI in healthy persons. However, risk decreased with increasing baseline cardiovascular risk, to the point that in patients at high cardiovascular risk, there was no additional risk associated with diclofenac compared with paracetamol or other NSAIDs. The other major study, from the SOS project, studied several million persons in four countries in Europe, comparing the use of many NSAIDs with non-use. That study found a slightly increased risk with diclofenac compared with non-use, but this was not different from other NSAIDs. Comparing risks with selectivity or potency found no effect of either. These studies refute the main hypotheses to explain the coronary risk of NSAIDs. Finding risk in healthy low-risk patients only questions the reality of a link between the use of the drugs and the occurrence of MI in these conditions. Biases or confounding may be the major reason for small increases in cardiovascular risks in healthy users of NSAIDs in real life.

journal_name

Drug Saf

journal_title

Drug safety

authors

Moore N

doi

10.1007/s40264-019-00900-8

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

301-318

issue

4

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-019-00900-8

journal_volume

43

pub_type

杂志文章,评审
  • Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports.

    abstract:BACKGROUND:Eosinophilic pneumonia (EP) has been noted in association with daptomycin use. The product labelling was recently updated to include EP in the Warnings and Precautions and Post-Marketing Experience sections. OBJECTIVE:The objective of this study was to analyse adverse event (AE) reports submitted to the US ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11597460-000000000-00000

    authors: Kim PW,Sorbello AF,Wassel RT,Pham TM,Tonning JM,Nambiar S

    更新日期:2012-06-01 00:00:00

  • Poisoning by thallium. A study of five cases.

    abstract::Thallium poisoning seldom occurs in Spain. This article reports 5 cases of thallium poisoning, of which 4 of the patients belonged to the same family. The cases occurred in or near Granada between 1985 and 1987. The symptoms were initially gastrointestinal (vomiting, abdominal pain, gastrointestinal haemorrhage, etc.)...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199005050-00006

    authors: Villanueva E,Hernandez-Cueto C,Lachica E,Rodrigo MD,Ramos V

    更新日期:1990-09-01 00:00:00

  • Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

    abstract::Osteoporosis is a major public health problem occurring primarily among the postmenopausal population. Osteoporosis is a preventable disease, but despite several advances in its prevention, treatment of the established disease to date remains a major challenge to be managed by primary care physicians. Stabilisation of...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411030-00004

    authors: Gennari C,Nuti R,Agnusdei D,Camporeale A,Martini G

    更新日期:1994-09-01 00:00:00

  • Discontinuation of beta-blockers and the risk of myocardial infarction in the elderly.

    abstract:BACKGROUND:It has been shown that the abrupt cessation of treatment with beta-adrenoceptor antagonists (beta-blockers) increases the risk of myocardial infarction in patients with hypertension. As beta-blockers differ in their pharmacokinetic and pharmacodynamic properties, this risk of discontinuation might also diffe...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章

    doi:10.2165/00002018-200730060-00008

    authors: Teichert M,de Smet PA,Hofman A,Witteman JC,Stricker BH

    更新日期:2007-01-01 00:00:00

  • The clinical implications of inhibition of the inducible form of cyclo-oxygenase.

    abstract::There are 2 isoenzymes of cyclo-oxygenase (COX). There is a constitutive enzyme COX-1 which has a wide tissue distribution. In addition there is an inducible enzyme COX-2 which has a restricted tissue distribution. The inducible enzyme COX-2 is responsible for the generation of prostaglandins at sites of tissue inflam...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199615040-00003

    authors: Richardson C,Emery P

    更新日期:1996-10-01 00:00:00

  • Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients.

    abstract::In August 2015, the US Food and Drug Administration (FDA) made the controversial decision to approve flibanserin (Addyi®) for women experiencing hypoactive sexual desire disorder. A number of factors contributed to disagreements regarding the FDA's decision, including the product's two prior failed FDA reviews, the un...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-015-0389-2

    authors: Baksh SN,Gellad WF,Alexander GC

    更新日期:2016-05-01 00:00:00

  • Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?

    abstract::The present review outlines the clinical relevance of pharmacokinetic drug interactions within the HMG-CoA reductase inhibitor class. These interactions can result in markedly increased or decreased plasma concentrations of some drugs within this class. However, the relationship between altered plasma concentrations a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326010-00002

    authors: Martin J,Krum H

    更新日期:2003-01-01 00:00:00

  • Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

    abstract:BACKGROUND AND OBJECTIVE:Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or 'statins', launched in the UK in March 2003. Our objective was to monitor the post-marketing safety of this drug, prescribed in primary care in England, using prescription-event monitor...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200730020-00005

    authors: Kasliwal R,Wilton LV,Cornelius V,Aurich-Barrera B,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.

    abstract::Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. The overall number of boxed warnings has grown in recent years as the US Food and Drug Administration (FDA) has approved more drugs on the basis of limited pre-marketing information and as n...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0419-8

    authors: Yeh JS,Sarpatwari A,Kesselheim AS

    更新日期:2016-08-01 00:00:00

  • An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.

    abstract:BACKGROUND:Academic medical centres face the need to care for patients with complex medical conditions, educate physicians-in-training and conduct research, all with increasingly constrained budgets. The adoption of new therapeutic technology presents challenges and opportunities in each of these areas. Severe sepsis r...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427150-00008

    authors: Fischer MA,Lilly CM,Churchill WW,Baden LR,Avorn J

    更新日期:2004-01-01 00:00:00

  • Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.

    abstract:BACKGROUND:Drug-drug interactions (DDIs) are a well known risk factor for adverse drug reactions. HMG-CoA reductase inhibitors ('statins') are a cornerstone in the treatment of dyslipidaemia and patients with dyslipidaemia are concomitantly treated with a variety of additional drugs. Since DDIs are associated with adve...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200528030-00007

    authors: Rätz Bravo AE,Tchambaz L,Krähenbühl-Melcher A,Hess L,Schlienger RG,Krähenbühl S

    更新日期:2005-01-01 00:00:00

  • Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.

    abstract:INTRODUCTION:Controversy exists about an association between angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), and thiazides (TZs) and the risk of malignant melanoma (MM), and non-melanoma skin cancer-basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). OBJECTIVE:The aim ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0487-9

    authors: Nardone B,Majewski S,Kim AS,Kiguradze T,Martinez-Escala EM,Friedland R,Amin A,Laumann AE,Edwards BJ,Rademaker AW,Martini MC,West DP

    更新日期:2017-03-01 00:00:00

  • Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

    abstract:BACKGROUND:Several efforts are under way to develop and test methods for prospective drug safety monitoring using large, electronic claims databases. Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signal...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11594770-000000000-00000

    authors: Wahl PM,Gagne JJ,Wasser TE,Eisenberg DF,Rodgers JK,Daniel GW,Wilson M,Schneeweiss S,Rassen JA,Patrick AR,Avorn J,Bohn RL

    更新日期:2012-05-01 00:00:00

  • A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

    abstract:BACKGROUND:The detection of new drug safety signals is of growing importance with ever more new drugs becoming available and exposure to medicines increasing. The task of evaluating information relating to safety lies with national agencies and, for international data, with the World Health Organization Programme for I...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023060-00004

    authors: Lindquist M,Ståhl M,Bate A,Edwards IR,Meyboom RH

    更新日期:2000-12-01 00:00:00

  • Comment on: "All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population".

    abstract:: ...

    journal_title:Drug safety

    pub_type: 评论,信件

    doi:10.1007/s40264-018-0670-2

    authors: Kawada T

    更新日期:2018-06-01 00:00:00

  • Safety issues in the use of methylphenidate. An American perspective.

    abstract::Methylphenidate is the most widely use psychotropic medication in children in the US. It is both well tolerated and efficacious in the treatment of attention deficit hyperactivity disorder, and is associated with few serious adverse effects. However, the abuse of methylphenidate for the purpose of experiencing a 'high...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199717030-00001

    authors: Rappley MD

    更新日期:1997-09-01 00:00:00

  • Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.

    abstract::Two Japanese regulatory agencies, the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency announced the implementation of a new review system called 'Conditional Approval,' specifically for the emerging field of regenerative medicine, in an amendment to the Pharmaceutical Affairs ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-017-0517-2

    authors: Inokuma Y

    更新日期:2017-06-01 00:00:00

  • Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.

    abstract:BACKGROUND:Screening large databases of spontaneous case reports of possible adverse drug reactions (ADRs) is an established method of identifying hitherto unknown adverse effects of medicinal products; however, there is a lack of consensus concerning the value of formal statistical screening procedures in guiding such...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11534410-000000000-00000

    authors: Alvarez Y,Hidalgo A,Maignen F,Slattery J

    更新日期:2010-06-01 00:00:00

  • Skin sensitivity and transdermal drug delivery. A review of the problem.

    abstract::Transdermal devices are now marketed for the delivery of systemic medication through the skin. Advantages associated with transdermal drug delivery include avoidance of first-pass metabolism and improved patient compliance. Drugs currently available by this route include scopolamine (hyoscine), nitroglycerin (glyceryl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199410020-00004

    authors: Carmichael AJ

    更新日期:1994-02-01 00:00:00

  • Carbamazepine overdose. Features of 33 cases.

    abstract::Review of the medical records of 2 major adult teaching hospitals for a 4-year period revealed 33 instances of carbamazepine overdose. These patients had a mean age of 30 years and 58% were known epileptics. They ingested a mean of 12g carbamazepine (range 1.6 to 45g), with 51% of cases involving other drugs, particul...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199308010-00010

    authors: Seymour JF

    更新日期:1993-01-01 00:00:00

  • Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.

    abstract:INTRODUCTION:The Bradford Hill criteria are a widely used, useful tool for the assessment of biomedical causation. We have examined their application to pharmacovigilance using the example of cisapride-induced QTc interval prolongation/arrhythmia. METHODS:A literature search was conducted using MEDLINE, EMBASE, Reacti...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析

    doi:10.2165/00002018-200730040-00006

    authors: Perrio M,Voss S,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.

    abstract::The biologics have revolutionized the treatment of rheumatoid arthritis (RA). However, there are still patients that are difficult to control and a cure is still not achievable. Tofacitinib, a Janus kinase (JAK) inhibitor is an orally available, new-in-class, disease-modifying anti-rheumatic drug with similar efficacy...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0430-0

    authors: Yamaoka K

    更新日期:2016-09-01 00:00:00

  • Renal effects of peptic ulcer therapy.

    abstract::Drugs used in the treatment of peptic ulcer disease may interact with the renal system in a variety of ways. Since many agents are eliminated by renal excretion, clearance of these agents may be reduced and half-life extended in the presence of renal insufficiency. The histamine H2-receptor antagonists may interfere w...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199207040-00004

    authors: Burgess E,Muruve D

    更新日期:1992-07-01 00:00:00

  • Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio.

    abstract::The main goal of pharmacological research in the field of topical corticosteroids (TCs) is to dissociate efficacy and adverse effects as much as possible. The optimal use of TCs, i.e. the careful evaluation of the benefit/risk ratio, depends on: (i) the chemical structure of the TC; (ii) the type of vehicle; (iii) the...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199410050-00005

    authors: Mori M,Pimpinelli N,Giannotti B

    更新日期:1994-05-01 00:00:00

  • Use of herbal medicines by patients receiving warfarin.

    abstract:BACKGROUND:Patients receiving warfarin therapy are discouraged from taking herbal medicines. Whether patients adhere to this advice and, if they do not, the types of products they use, are not known. OBJECTIVE:The objective of this observational study was to estimate the magnitude of use of herbal medicines among Chin...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200326080-00004

    authors: Wong RS,Cheng G,Chan TY

    更新日期:2003-01-01 00:00:00

  • Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands.

    abstract:BACKGROUND:Medication-related adverse events (MRAEs) form a large proportion of all adverse events in hospitalized patients and are associated with considerable preventable harm. Detailed information on harm related to drugs administered during hospitalization is scarce. Knowledge of the nature and preventability of MR...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11536800-000000000-00000

    authors: Hoonhout LH,de Bruijne MC,Wagner C,Asscheman H,van der Wal G,van Tulder MW

    更新日期:2010-10-01 00:00:00

  • Association between leukotriene-modifying agents and suicide: what is the evidence?

    abstract::The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LT...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11587260-000000000-00000

    authors: Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD

    更新日期:2011-07-01 00:00:00

  • Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

    abstract:BACKGROUND:Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited. OBJECTIVE:To retrospectively assess the safety profile of interferon-beta-1a therapy with respect to liver function durin...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00002018-200326110-00006

    authors: Francis GS,Grumser Y,Alteri E,Micaleff A,O'Brien F,Alsop J,Stam Moraga M,Kaplowitz N

    更新日期:2003-01-01 00:00:00

  • Immunisation and type 1 diabetes mellitus: is there a link?

    abstract::Recent evidence from animal studies has raised the possibility that immunisation by vaccines can influence the pathogenesis of type I (insulin-dependent) diabetes mellitus. In non-obese diabetic mice and biobreeding rats, complete Freund's adjuvant and bacillus Calmette-Guérin (BCG) vaccine have successfully been used...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199920030-00001

    authors: Hiltunen M,Lönnrot M,Hyöty H

    更新日期:1999-03-01 00:00:00

  • Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports.

    abstract:INTRODUCTION AND OBJECTIVE:Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, wh...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-015-0383-8

    authors: Klein K,Scholl JH,Vermeer NS,Broekmans AW,Van Puijenbroek EP,De Bruin ML,Stolk P

    更新日期:2016-02-01 00:00:00